Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)

Dieras V; Miles D.; Verma S.

首页> 外文期刊>The lancet oncology >Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)

【24h】

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)

机译：Trastuzumab emtansine与Capecitabine Plus Lapatinib患者在先前治疗的Her2阳性晚期乳腺癌（艾米利亚）：对随机开放标签，第3阶段试验（Vol 18，PG 732,2017）的最终整体生存结果的描述性分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第12期|共1页
作者
Dieras V; Miles D.; Verma S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017) [J] . Dieras V, Miles D., Verma S. The lancet oncology . 2018,第12期

机译：Trastuzumab emtansine与Capecitabine Plus Lapatinib患者在先前治疗的Her2阳性晚期乳腺癌（艾米利亚）：对随机开放标签，第3阶段试验（Vol 18，PG 732,2017）的最终整体生存结果的描述性分析
2. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017) [J] . Dieras V, Miles D., Verma S. Journal of Turbulence . 2017,第8期

机译：Trastuzumab emtansine与Capecitabine Plus Lapatinib患者在先前治疗的Her2阳性晚期乳腺癌（艾米利亚）：对随机开放标签，第3阶段试验（Vol 18，PG 732,2017）的最终整体生存结果的描述性分析
3. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J] . Dieras Veronique, Miles David, Verma Sunil, The lancet oncology . 2017,第6期

机译：Trastuzumab emtansine与先前治疗Her2阳性晚期乳腺癌（Emilia）的患者的辛核特征（emilia）：对随机开放标签，第3阶段试验的最终总生存结果的描述性分析
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised open-label phase 3 trial [O] . Véronique Diéras, David Miles, Sunil Verma, -1

机译：曲妥珠单抗Emtansine与卡培他滨加拉帕替尼治疗先前治疗过的HER2阳性晚期乳腺癌（EMILIA）的患者：一项随机开放标签的3期临床试验的最终总体生存率的描述性分析
6. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [O] . Véronique Diéras, David Miles, Sunil Verma, 2017

机译：Trastuzumab Emtansine与Capecitabine Plus Lapatinib患者在先前治疗的Her2阳性晚期乳腺癌（艾米利亚）：对随机开放标签，第3阶段试验的最终总生存率的描述性分析

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)

著录项

相似文献

相关主题

期刊订阅